Head-to-head · Cost-Efficiency Index
Vea Health vs BeyondMD
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Vea Health
Shoppers comfortable completing a full intake before seeing any price, in exchange for a broader microdosing menu.
Visit Vea HealthBeyondMD
Shoppers who want a named clinical team on a broader wellness platform, not just a single-purpose GLP-1 funnel.
Visit BeyondMDThe verdict
Vea Health takes it, leading the Cost-Efficiency Index 54 to 53. Vea Health is a men's-health-and-longevity telehealth brand selling both standard-dose and 'microdosing' tiers of compounded semaglutide and tirzepatide alongside sermorelin, NAD+, and glutathione. BeyondMD still earns a C — Shoppers who want a named clinical team on a broader wellness platform, not just a single-purpose GLP-1 funnel.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Vea Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Vea Health | BeyondMD |
|---|---|---|
| Cost-Efficiency Index | 54/100 | 53/100 |
| Semaglutide / mo | Not disclosed | $125/mo (starting dose, compounded) |
| Tirzepatide / mo | Not disclosed | $199/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | — | $1,500 |
| Tirzepatide / yr (modeled) | — | $2,388 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | Yes | Yes |
| Brand-name access | Yes | Compounded only |
| Rank here | #366 | #370 |
Vea Health
54/100Where the value is
- Verified LegitScript certification with a working checker link (seal ID 48955268)
- Offers a genuine microdosing tier for both semaglutide and tirzepatide alongside the standard dose
- Repeats the FDA compounded-medication disclaimer on every page, and states 'Provider approval required. Not all patients qualify' rather than implying automatic approval
The tradeoffs
- Zero pricing is published anywhere on the public site — the entire catalog is gated behind the intake quiz
- No compounding pharmacy is named anywhere; the site only says 'domestic, pharmacy-grade suppliers' and 'FDA-registered, cGMP-certified facilities'
BeyondMD
53/100Where the value is
- Individually named clinicians appear on the site rather than only a corporate entity: John Marley Bernard Jr., MD; Hollie Ann Hall, APRN-C; Jordan Dorsey, NP
- LegitScript-certified with the verification seal displayed
- All 50 states served per the site's own claim
The tradeoffs
- The site's own pages disagree with themselves on the tirzepatide starting price — one page says '$199,' another says '$209' — neither dated nor reconciled anywhere public
- No compounding pharmacy is named, only generic 'fully licensed U.S. 503A pharmacies' language
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.